Brussels (Belgium), 25 April 2018 - 18:00 (CEST) - regulated information -

  • Revenue reached € 1.07 billion: -5%, -1% CER; adjusted for allergy drug divestiture in 2017: +0%; +4% CER
  • UCB's main five products reached € 839 million (-2%, +8% CER)
  • R&D update: Cimzia® available for women with chronic inflammatory disease throughout the pregnancy journey; UCB0107 enters clinical phase 1; Element Genomics strengthens research platform; agreement to acquire midazolam nasal spray in epilepsy
  • Financial outlook 2018 confirmed: Revenue expected to reach € 4.5 - 4.6 billion, recurring EBITDA2 should reach € 1.3 - 1.4 billion, Core EPS of € 4.30 - 4.70

Attachments

  • Original document
  • Permalink

Disclaimer

UCB SA published this content on 25 April 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 April 2018 16:12:08 UTC